Globus Medical CEO Daniel Scavilla’s salary rose to $4.8 million in 2024, according to the company’s April 25 Securities and Exchange Commission proxy filing. Compensation packages for executives ...

Globus Medical Inc. stock grades by Barron's. View GMED fundamental and sentiment analysis powered by MarketGrader.

According to Benzinga Pro, Globus Medical's peer group average for short interest as a percentage of float is 4.39%, which ...

Decades of market research shows that the best-performing stocks often have an 80 or higher RS Rating in the early stages of ...

Nationwide, MOB sales were $1.5 billion in Q1. That was down 44% from Q4 2024 and marks the lowest quarter of sales in the ...

Globus Medical currently trades at $75.69 per share and has shown little upside over the past six months, posting a middling ...

Learn more about whether Globus Medical, Inc. or LeMaitre Vascular, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Globus Medical, Inc. shines with strong Q4 results & Nevro acquisition, boosting its market position. Click here to find out ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

compete successfully (including without limitation success in convincing surgeons to use Globus Medical or Nevro products and ...

Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.